Understanding how certain proteins contribute to the toxicity in Parkinson's Disease
Exploiting New Fibril Structures to Understand the Biophysical Basis for Oligomerization and Toxicity of Alpha-Synuclein
This study is looking at how a protein related to Parkinson's Disease can misfold and form harmful shapes, with the hope of finding new ways to treat the condition and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Minnesota NIH-funded |
| Lab location | 1 site (Minneapolis, United States) |
| Project ID | NIH-10909161 on NIH RePORTER |
What this research studies
This research investigates the early-stage oligomers of alpha-Synuclein, a protein linked to Parkinson's Disease, to understand how they misfold and assemble into toxic forms. By examining the interactions between amino acids in these proteins, the study aims to identify specific structural motifs that contribute to their toxicity. The research employs advanced biophysical techniques to analyze these interactions, which could lead to new therapeutic targets for treating Parkinson's Disease. Patients may benefit from insights gained into the molecular mechanisms of the disease, potentially leading to improved treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's Disease or those at risk of developing it.
Not a fit: Patients with other neurodegenerative disorders unrelated to alpha-Synuclein may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for Parkinson's Disease by targeting the toxic forms of alpha-Synuclein.
How similar studies have performed: Previous research has shown promise in targeting protein misfolding in neurodegenerative diseases, suggesting that this approach could yield significant insights.
Where this research is happening
Minneapolis, United States
- University of Minnesota — Minneapolis, United States (Active)
Researchers
- Principal investigator: Sachs, Jonathan N — University of Minnesota
- Study coordinator: Sachs, Jonathan N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.